HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A randomized, controlled study of autologous therapy with bone marrow-derived aldehyde dehydrogenase bright cells in patients with critical limb ischemia.

AbstractOBJECTIVES:
The safety and efficacy of direct intramuscular injections of aldehyde dehydrogenase bright (ALDH(br)) cells isolated from autologous bone marrow mononuclear cells (ABMMNCs) and ABMMNCs were studied in patients with critical limb ischemia (CLI) who were not eligible for percutaneous or surgical revascularization.
BACKGROUND:
Many CLI patients are not candidates for current revascularization procedures, and amputation rates are high in these patients. Cell therapy may be a viable option for CLI patients.
METHODS:
Safety was the primary objective and was evaluated by occurrence of adverse events. Efficacy, the secondary objective, was evaluated by assessment of Rutherford category, ankle-brachial index (ABI), transcutaneous partial pressure of oxygen (TcPO(2)), quality of life, and pain.
RESULTS:
ALDH(br) cells and ABMMNCs were successfully administered to all patients. No therapy-related serious adverse events occurred. Patients treated with ALDH(br) cells (n = 11) showed significant improvements in Rutherford category from baseline to 12 weeks (mean, 4.09 ± 0.30 to 3.46 ± 1.04; P = 0.05) and in ABI at 6 (mean, 0.22 ± 0.19 to 0.30 ± 0.24; P = 0.02), and 12 weeks (mean, 0.36 ± 0.18; P = 0.03) compared with baseline. Patients in the ABMMNC group (n = 10) showed no significant improvements at 6 or 12 weeks in Rutherford category but did show improvement in ABI from baseline to 12 weeks (0.38 ± 0.06 to 0.52 ± 0.16; P = 0.03). No significant changes from baseline were noted in ischemic ulcer grade or TcPO(2) in either group.
CONCLUSIONS:
Administration of autologous ALDH(br) cells appears to be safe and warrants further study in patients with CLI.
AuthorsEmerson C Perin, Guilherme Silva, Amir Gahremanpour, John Canales, Yi Zheng, Maria G Cabreira-Hansen, Farrell Mendelsohn, Nicolas Chronos, Rebecca Haley, James T Willerson, Brian H Annex
JournalCatheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (Catheter Cardiovasc Interv) Vol. 78 Issue 7 Pg. 1060-7 (Dec 01 2011) ISSN: 1522-726X [Electronic] United States
PMID21594960 (Publication Type: Clinical Trial, Phase I, Journal Article, Multicenter Study, Randomized Controlled Trial)
CopyrightCopyright © 2011 Wiley Periodicals, Inc.
Chemical References
  • Aldehyde Dehydrogenase
Topics
  • Aged
  • Aged, 80 and over
  • Aldehyde Dehydrogenase (metabolism)
  • Ankle Brachial Index
  • Bone Marrow Cells (enzymology)
  • Bone Marrow Transplantation (adverse effects)
  • Cell Separation (methods)
  • Critical Illness
  • Double-Blind Method
  • Extremities (blood supply)
  • Female
  • Flow Cytometry
  • Hemodynamics
  • Humans
  • Injections, Intramuscular
  • Ischemia (diagnosis, enzymology, physiopathology, surgery)
  • Male
  • Middle Aged
  • Recovery of Function
  • Regional Blood Flow
  • Time Factors
  • Transplantation, Autologous
  • Treatment Outcome
  • United States

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: